Last reviewed · How we verify
NCT06831123
Pathways 2 Success
Phase 1, PHASE2 trial testing L2B in Conduct Disorder in 120 participants. Currently enrolling.
28 February 2027
Quick facts
| Lead sponsor | University of Minnesota |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 120 |
| Start date | 12 March 2025 |
| Primary completion | 28 February 2027 |
| Estimated completion | 28 February 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- L2B
- L2B + App
- skills for success
Conditions studied
- Conduct Disorder — all drugs for Conduct Disorder →
- Oppositional Defiant Disorder — all drugs for Oppositional Defiant Disorder →
Sponsor
University of Minnesota
Who can join
Adults 13 to 17, any sex, with Conduct Disorder or Oppositional Defiant Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study involves a 3-arm randomized controlled trial designed to investigate the feasibility and acceptability of three preventive interventions designed to reduce risk for escalations in adolescent conduct problems. High school students identified to be at risk for conduct problems will be randomly assigned to one of three intervention options, including a mindfulness-based program, a mindfulness-based program augmented by a new mobile app, and a life skills program. Assessments related to intervention outcomes will be completed by adolescents, parents/guardians, and teachers at baseline, 2 weeks post-intervention, and at a 3-month follow-up.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06831123
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Conduct Disorder
Currently open trials in the same condition.
- NCT06657430 — A Study on the Preference of Risperidone Dosage Forms · recruiting
- NCT05802758 — CFT-focused Mental Health Intervention With Exposure Training for Youngsters · NA · recruiting
- NCT05637320 — Big Feelings: A Study on Children's Emotions in Therapy · NA · recruiting
- NCT04631042 — Developing Brain, Impulsivity and Compulsivity · recruiting
- NCT05449002 — Digital Single Session Intervention for Youth Mental Health · NA · recruiting
Other University of Minnesota trials
Trials by the same sponsor.
- NCT02421497 — MRI Technical Development and Applications in Kidney Disease · not yet recruiting
- NCT04100109 — Evaluating the Metabolic Effects of Polylactose: A Novel Prebiotic · NA · withdrawn
- NCT05454306 — Anser Clavicle Pin for Surgical Management of Midshaft Clavicle Fractures · NA · withdrawn
- NCT03192007 — Multi-Parametric MRI for Renal Transplantation · not yet recruiting
- NCT04940533 — Pharmacokinetics of CFTR Modulators in Pregnant Individuals and in Postpartum Breastfeeding Mothers · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06831123 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Minnesota
- Last refreshed: 13 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06831123.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing